EPO906 in Carcinoid and Other Neuroendocrine Tumors

Exclusion Criteria

• •Patients with symptomatic CNS metastases or leptomeningeal involvement
• •Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression.
• •Patients with bone metastases as the only site(s) of measurable disease
• •Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease)
• •Patients who have been previously treated with radioactive directed therapies
• •Patients who have been previously treated with epothilone
• •Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1
• •Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports
• •Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ
• •Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae
• •Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits
• •HIV+ patients
• •Pregnant or lactating females.